Review

Ratin DSIJ / 13 Aug 2026 / Categories: Flash News Investment App, Recommendations

Review of 1 stock recommended in the past

Review of 1 stock recommended in the past [EasyDNNnews:PaidContentStart]

GLAND PHARMA LTD
Ticker : 543245
FV: ₹1
52-Week H/L: ₹2989.25/1575.00

We had recommended Gland Pharma Ltd at Rs 2,446.25 per share in Vol. 42, Issue 38 (July 2, 2026). Gland Pharma is one of India’s leading injectable-focused pharmaceutical companies, with a strong presence in regulated markets such as the US and Europe. Gland reported a strong Q1 FY27, with revenue rising 20 per cent year-on-year and 3 per cent quarter-on-quarter to Rs 1,800.3 crore. EBITDA increased 34 per cent year-on-year to Rs 493 crore, though it declined 4 per cent sequentially, while PAT rose 47 per cent year-on-year to Rs 317 crore despite a 14 per cent quarter-on-quarter decline. The company launched four molecules in the US during the quarter and now has 389 ANDA filings, including 342 approvals. Its CDMO business contributed 50 per cent of revenue and grew 20 per cent year-on-year. Importantly, a global CDMO partnership carries annualised revenue potential of USD 90-100 million once fully commercialised, with revenues expected from 2029. We continue to recommend HOLD.

[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]

To read the entire article, you must be a FNI Weekly Subscriber.

[EasyDNNnews:UnPaidContentEnd]